Aurdan Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Aurdan Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$577K	Sell	10,022 -18	-0.2%	-$1.03K	0.15%	58
2026 Q1	$609K	Buy	10,040 +18	+0.2%	+$1.05K	0.18%	59
2025 Q4	$541K	Sell	10,022 -106	-1%	-$5.1K	0.17%	61
2025 Q3	$457K	Sell	10,128 -35	-0.3%	-$1.64K	0.15%	66
2025 Q2	$470K	Hold	10,163	–	–	0.16%	63
2025 Q1	$620K	Buy	10,163 +163	+2%	+$9.5K	0.23%	57
2024 Q4	$566K	Buy	+10,000	New	+$559K	0.22%	56

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Aurdan Capital Management's BMY Position: Q2 2026 in Review

Aurdan Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.18% in Q2 2026, selling an estimated $1.03K and leaving 10,022 shares worth $577K. The position accounts for 0.15% of the portfolio, ranked #58.

Aurdan Capital Management first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $620K in Q1 2025. 941 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Aurdan Capital Management held 10,022 shares of Bristol-Myers Squibb worth $577K as of Q2 2026.
Aurdan Capital Management sold 18 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.03K.
Bristol-Myers Squibb made up 0.15% of Aurdan Capital Management's portfolio in Q2 2026, its #58 holding.
Aurdan Capital Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
Aurdan Capital Management's Bristol-Myers Squibb position peaked at $620K in Q1 2025.
941 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Aurdan Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.